-
2 weeks ago | 
healio.com | Anthony DeFino
Key takeaways: An analysis found a slight predominance of late in-the-bag IOL dislocations in men. Capsular tension rings may be a protective factor against dislocation. Late in-the-bag IOL dislocation has a number of risk factors, including trauma-related conditions, as well as protective factors, according to a study published in the Journal of Cataract & Refractive Surgery.
-
2 weeks ago | 
healio.com | Arun C. Gulani |Anthony DeFino
ORLANDO — In this Healio Video Perspective from Telling It Like It Is, Arun C. Gulani, MD, discusses a panel on managing complex corneal and cataract cases and how the meeting helps to advance ophthalmic education. He also encouraged ophthalmologists to attend next year’s Sunshine Eye & Retina meeting, which will take place March 26-29, 2026, in Miami. “It is very important that this meeting maintain its momentum,” he said.
-
2 weeks ago | 
healio.com | Anthony DeFino
Key takeaways: Encelto is the first FDA-approved treatment for macular telangiectasia type 2. The cell therapy slows the loss of macular photoreceptors through continuous delivery of ciliary neurotrophic factor. The FDA approved Encelto, an encapsulated cell therapy, for the treatment of macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.
-
3 weeks ago | 
healio.com | Anthony DeFino |Christine Klimanskis |Preeya K. Gupta
Key takeaways: The lens will launch in the U.S. in May. It is designed to provide more uninterrupted light distribution and less light scatter. Alcon introduced the Clareon PanOptix Pro trifocal IOL, which will be commercially available in the U.S. in May, for patients with cataracts, according to a press release.
-
4 weeks ago | 
healio.com | Anthony DeFino |Christine Klimanskis |Susan P Mollan
Nonarteritic anterior ischemic optic neuropathy (NAION) is a relatively rare neuro-ophthalmic condition, occurring in between two to 10 people per 100,000 in the general population. NAION typically occurs in people aged older than 50 years, with type 2 diabetes being a strong risk factor. Recently, there have been reports of prescriptions of synthetic incretin mimetics being associated with the development of ischemic optic neuropathy.
-
1 month ago | 
healio.com | I. Paul Singh |Anthony DeFino |Christine Klimanskis
Read more ORLANDO — In this Healio Video Perspective from Telling It Like It Is, I. Paul Singh, MD, shares how Dextenza can decrease the topical drop burden of steroids and improve efficiency of ophthalmic surgery. According to Singh, Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix) reduces the amount of time ophthalmologists spend on patient education and follow-up, as well as time spent in discussions with insurance companies and pharmacies.
-
1 month ago | 
healio.com | Anthony DeFino |Christine Klimanskis
Key takeaways: Remote tonometry allows patients to perform diurnal IOP curves. Genetic risk scoring may help determine who is at risk for glaucoma progression. Emerging technologies, including remote tonometry and genetic risk scoring, hold promise for more efficient glaucoma care, according to a speaker at the American Glaucoma Society meeting.
-
1 month ago | 
healio.com | Anthony DeFino |Christine Klimanskis
Key takeaways: ATSN-201 is being evaluated for the treatment of X-linked retinoschisis. The gene therapy previously received orphan drug and rare pediatric disease designations. Editor’s note: This is a developing news story. Please check back soon for updates. The FDA granted fast track designation to ATSN-201 for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.
-
1 month ago | 
healio.com | Anthony DeFino |Christine Klimanskis
Key takeaways: The new drug application is supported by 3-year data from the STAR study. If approved, SYD-101 would be the first pharmaceutical treatment to slow the progression of pediatric myopia in the U.S.The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription Drug User Fee Act date of Oct. 23, according to a press release from Sydnexis.
-
1 month ago | 
healio.com | Anthony DeFino |Christine Klimanskis
Key takeaways: The impact of cost must be considered when selecting a glaucoma treatment. Earlier glaucoma diagnosis and treatment will reduce costs. Ophthalmologists must consider the cost-effectiveness of available treatment options for glaucoma and the impact this may have on patients, according to a speaker at the American Glaucoma Society meeting.
